Home/ Stocks/ BIVI

BioVie, Inc. Common Stock

BIVI XNAS

$0.95 -1.08 (-53.19%) ▼ 15-min delayed

Open

$1.36

High

$1.38

Low

$0.82

Volume

7.09M

Market Cap

$15.39M

About BioVie, Inc. Common Stock

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 13 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2026	$0	$-5,270,299	$-0.70
Q2 2026	$0	$-6,069,475	$-0.77
Q1 2026	$0	$-5,087,557	$-0.98
FY 2025	$0	$-17,542,120	$-12.12

TickerDaily Coverage

Why Is BioVie, Inc. Common Stock (BIVI) Stock Down 50.5% Today?

Penny Stocks Marcus Rivera · 4h ago

BioVie Inc. shares tanked 50.5% Thursday, plummeting from $2.04 to $1.025 on volume 8.1x above...

View All Coverage →

Get BIVI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BioVie, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.